

ASX ANNOUNCEMENT

ASX:VHL OTCQB:VHLUF

1 September 2025

ASX Market Announcements
ASX Limited
Level 4
Stock Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

RESULTS OF GENERAL MEETING

Vitasora Health Limited (ASX:VHL; OTCQB:VHLUF) ("Vitasora" or the "Company"), hereby provides the results of its general meeting of shareholders held on 1 September 2025.

Information required to be disclosed by the Company in accordance with Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act is attached.

All resolutions were passed on a poll. Details of resolutions, the proxies received, and the votes cast on the poll in respect of each resolution are set out in the attached results summary.

For and on behalf of the Board:
Vitasora Health Limited

JUSTIN MOUCHACCA
Company Secretary

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Vitasora Health Limited
P: +61 408 462 873
E: marjan@vitasorahealth.com

Mr Nicholas Smedley
Non-Executive Chairman
Vitasora Health Limited
P: +61 447 074 160
E: nicholas@vitasorahealth.com

This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.

About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:VHLUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.vitasorahealth.com.au

ASX ANNOUNCEMENT

ASX:VHL OTCQB:VHLUE

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us/> or for [wheezo®](#)

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited

For personal use only

ASX ANNOUNCEMENT
ASX:VHL OTCQB:VHLUF

Vitasora Health Limited
2025 General Meeting
Monday, 1 September 2025 - Voting Results

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth)

Resolution Details			Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Resolution Type	S or P	For	Against	Proxy's Discretion	Abstain/ Excluded	For	Against	Abstain	Carried/ Not Carried
1.	Ratification and approval of prior issue of Shares	Ordinary	P	251,261,709 98.69%	2,068,178 0.81%	1,271,430 0.50%	3,131,364 -	252,533,139 99.19%	2,068,178 0.81%	131,364 -	Carried
2.	Approval to issue Tranche 2 Placement Shares	Ordinary	P	254,235,209 98.71%	2,070,441 0.80%	1,271,430 0.49%	155,601 -	255,506,639 99.20%	2,070,441 0.80%	155,601 -	Carried
3.	Approval of Issue of Placement Shares to Mr Nicholas Smedley, Director of the Company	Ordinary	P	252,960,942 98.26%	3,197,035 1.24%	1,295,312 0.50%	279,392 -	254,256,254 98.76%	3,197,035 1.24%	279,392 -	Carried
4	Approval of Issue of Placement Shares to Mr Marjan Mikel, Director of the Company	Ordinary	P	252,918,970 98.25%	3,189,285 1.24%	1,303,062 0.51%	321,364 -	254,222,032 98.76%	3,189,285 1.24%	321,364 -	Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

For personal use only